• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重 COVID-19 的治疗策略:来自意大利传染病和热带病学会(SIMIT)的立场文件。

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).

机构信息

Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.

出版信息

Clin Microbiol Infect. 2021 Mar;27(3):389-395. doi: 10.1016/j.cmi.2020.12.011. Epub 2021 Jan 18.

DOI:10.1016/j.cmi.2020.12.011
PMID:
33359375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833273/
Abstract

SCOPE

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting.

METHODS

The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19.

IMPLICATIONS

After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.

摘要

范围

严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)感染已成为大流行,在全球造成近 100 万人死亡。目前,针对 2019 年冠状病毒病(COVID-19)的标准治疗方法尚未明确,因为随机或观察性研究的证据存在相互矛盾的结果,这导致治疗指南迅速改变。我们的目的是对 COVID-19 管理的现有文献进行叙述性总结,以便将当前的证据和对正在一线治疗患者的专家对数据的解释结合起来。

方法

专家组对每个可能的治疗方法进行了详细的文献回顾,并最终对随机临床试验的新闻稿进行了回顾。对与该主题相关的出版物进行了归纳性的 PubMed 搜索,包括所有已进行的临床试验。结果是一个流程图,列出了 COVID-19 患者的治疗指征。

意义

在大流行发生 6 个月后,在可能的第二波冠状病毒袭击欧洲之前,评估哪些药物被证明有效非常重要,同时也要考虑到许多随机临床试验的结果仍在等待之中。事实上,在 COVID-19 的治疗方法中,只有糖皮质激素与死亡率的显著降低相关,这已在发表的随机对照试验中得到证实。迫切需要新的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1b9/7833273/c003a814167d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1b9/7833273/c003a814167d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1b9/7833273/c003a814167d/gr1_lrg.jpg

相似文献

1
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).严重 COVID-19 的治疗策略:来自意大利传染病和热带病学会(SIMIT)的立场文件。
Clin Microbiol Infect. 2021 Mar;27(3):389-395. doi: 10.1016/j.cmi.2020.12.011. Epub 2021 Jan 18.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.双盲、随机、对照临床试验评估同种异体间充质基质细胞治疗 COVID-19 所致急性呼吸窘迫综合征患者的疗效(COVID-AT):一项随机对照试验的研究方案的结构总结。
Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1.
6
Electroencephalography during SARS-CoV-2 outbreak: practical recommendations from the task force of the Italian Society of Neurophysiology (SINC), the Italian League Against Epilepsy (LICE), and the Italian Association of Neurophysiology Technologists (AITN).SARS-CoV-2 爆发期间的脑电图:来自意大利神经生理学会(SINC)、意大利癫痫协会(LICE)和意大利神经生理技术协会(AITN)工作组的实用建议。
Neurol Sci. 2020 Sep;41(9):2345-2351. doi: 10.1007/s10072-020-04585-1. Epub 2020 Jul 21.
7
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.尼他唑胺联合阿扎那韦/利托那韦治疗中重度 COVID-19(NACOVID)的疗效和安全性:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 4;22(1):3. doi: 10.1186/s13063-020-04987-8.
8
Spirometry during the SARS-CoV-2 pandemic. Guidelines and practical advice from the expert panel of Respiratory Physiopathology Assembly of Polish Respiratory Society.SARS-CoV-2 大流行期间的肺量测定。波兰呼吸学会呼吸病理生理学分会专家组的指南和实用建议。
Adv Respir Med. 2020;88(6):640-650. doi: 10.5603/ARM.a2020.0186.
9
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
10
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.直接针对新型冠状病毒的抗病毒药物:阿奇霉素(DAWn-AZITHRO),一项针对新型冠状病毒的新型抗病毒药物的随机、多中心、开放标签、适应性、概念验证临床试验-阿奇霉素试验。
Trials. 2021 Feb 9;22(1):126. doi: 10.1186/s13063-021-05033-x.

引用本文的文献

1
Association between Pulmonary Aspergillosis and Reactivation in Critically Ill COVID-19 Patients: A Prospective Observational Cohort Study.COVID-19 危重症患者肺部曲霉菌病与再激活的相关性:一项前瞻性观察队列研究。
Viruses. 2023 Nov 15;15(11):2260. doi: 10.3390/v15112260.
2
The Association of Procalcitonin and C-Reactive Protein with Bacterial Infections Acquired during Intensive Care Unit Stay in COVID-19 Critically Ill Patients.降钙素原和C反应蛋白与新型冠状病毒肺炎危重症患者重症监护病房住院期间获得性细菌感染的相关性
Antibiotics (Basel). 2023 Oct 12;12(10):1536. doi: 10.3390/antibiotics12101536.
3
Liver Damage and Impaired Coagulation in COVID-19 Patients: A Case Series.

本文引用的文献

1
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
2
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
3
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
COVID-19患者的肝损伤与凝血功能障碍:病例系列
Diseases. 2023 Oct 13;11(4):141. doi: 10.3390/diseases11040141.
4
Reduced Reliability of Procalcitonin (PCT) as a Biomarker of Bacterial Superinfection: Concerns about PCT-Driven Antibiotic Stewardship in Critically Ill COVID-19 Patients-Results from a Retrospective Observational Study in Intensive Care Units.降钙素原(PCT)作为细菌二重感染生物标志物的可靠性降低:对危重症COVID-19患者中PCT驱动的抗生素管理的担忧——来自重症监护病房的一项回顾性观察研究结果
J Clin Med. 2023 Sep 24;12(19):6171. doi: 10.3390/jcm12196171.
5
Critical COVID-19 patients through first, second, and third wave: retrospective observational study comparing outcomes in intensive care unit.新冠重症患者在第一波、第二波和第三波疫情期间:比较重症监护病房治疗结果的回顾性观察研究
J Thorac Dis. 2023 Jun 30;15(6):3218-3227. doi: 10.21037/jtd-22-764. Epub 2023 May 26.
6
Retrospective Analysis of the Outcome of Hospitalized COVID-19 Patients with Coexisting Metabolic Syndrome and HIV Using Multinomial Logistic Regression.采用多项逻辑回归分析合并代谢综合征和 HIV 的住院 COVID-19 患者结局的回顾性分析。
Int J Environ Res Public Health. 2023 May 12;20(10):5799. doi: 10.3390/ijerph20105799.
7
Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study.所有 COVID-19 疾病危重症患者从添加托珠单抗联合糖皮质激素治疗中获益吗?一项回顾性队列研究。
Viruses. 2023 Jan 20;15(2):294. doi: 10.3390/v15020294.
8
Role of Selective Digestive Decontamination in the Prevention of Ventilator-Associated Pneumonia in COVID-19 Patients: A Pre-Post Observational Study.选择性消化道去污在预防新型冠状病毒肺炎患者呼吸机相关性肺炎中的作用:一项前后对照观察性研究
J Clin Med. 2023 Feb 10;12(4):1432. doi: 10.3390/jcm12041432.
9
The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury.肥胖与新冠后遗症:低氧血症、血栓性炎症和血管内皮损伤。
Front Cardiovasc Med. 2023 Feb 7;10:1062491. doi: 10.3389/fcvm.2023.1062491. eCollection 2023.
10
High Incidence of Candidemia in Critically Ill COVID-19 Patients Supported by Veno-Venous Extracorporeal Membrane Oxygenation: A Retrospective Study.接受静脉-静脉体外膜肺氧合支持的危重症COVID-19患者念珠菌血症的高发生率:一项回顾性研究
J Fungi (Basel). 2023 Jan 14;9(1):119. doi: 10.3390/jof9010119.
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
4
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
5
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.46 例重症 COVID-19 患者接受免疫血浆治疗后的死亡率降低:一项概念验证性单臂多中心试验。
Haematologica. 2020 Dec 1;105(12):2834-2840. doi: 10.3324/haematol.2020.261784.
6
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.新冠肺炎重症肺炎患者恢复期血浆的随机临床试验。
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
7
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性:一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
8
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).恢复期血浆治疗印度成人中度 COVID-19 的管理:开放标签 II 期多中心随机对照试验(PLACID 试验)。
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
9
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
10
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.